Loading...
20/20 Biolabs, Inc. Common Stock
AIDX•NASDAQ
Healthcare
Medical - Devices
$1.83
$-0.05(-2.66%)
U.S. Market opens in 51h 5m20/20 Biolabs, Inc. Common Stock (AIDX) AI-Powered Stock Analysis
See how 20/20 Biolabs, Inc. Common Stock scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer20/20 Biolabs, Inc. Common Stock (AIDX) Stock Overall Grade
20/20 Biolabs, Inc. Common Stock’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to 20/20 Biolabs, Inc. Common Stock's overall stock rating.
Forecast
C+Score
56/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
51/100Key Ratios
BScore
67/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/10020/20 Biolabs, Inc. Common Stock (AIDX) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 56/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (67/100, B) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each 20/20 Biolabs, Inc. Common Stock stock grade, including financials, comparisons, and forecasts.